Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa

Malaria Journal

Volumn 5, Issue , 2006, Pages

  Happi, Christian T ^a,b   Gbotosho, Grace O ^a   Folarin, Onikepe A ^a   Milner, Danny ^b   Sarr, Ousmane ^c   Sowunmi, Akintunde ^a   Kyle, Dennis E ^d   Milhous, Wilbur K ^d   Wirth, Dyann F ^b   Oduola, Ayoade M J ^e  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CYTOCHROME B; PROGUANIL; TYROSINE;

ADOLESCENT; ADULT; AFRICA; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; CYTB GENE; GENE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHILD; CODON; CYTOCHROMES B; DNA, PROTOZOAN; DRUG RESISTANCE; HUMANS; MALARIA, FALCIPARUM; MALAWI; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NAPHTHOQUINONES; NIGERIA; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGUANIL; PROTOZOAN PROTEINS; SENEGAL; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; TRAVEL;

EID: 33750022628     PISSN: 14752875     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-5-82     Document Type: Article

References (35)

1. Milhous WK: Development of new drugs for chemoprophylaxis of malaria. Med Trop (Mars) 2001, 61:48-50.
2. Matsuu A, Koshida Y, Kawahara M, Inoue K, Ikadai H, Hikasa Y, Okano S, Higuchi S: Efficacy of atovaquone against Babesia gibsoni in vivo and in vitro. Vet Parasitol 2004, 124:9-18.
3. Araujo FG, Huskinson J, Remington JS: Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother 1991, 35:293-299.
4. Fry M, Pudney M: Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy- 1,4-naphthoquinone (566C80). Biochem Pharmacol 1992, 43:1545-1553.
5. Srivastava IK, Rottenberg H, Vaidya AB: Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 1997, 272:3961-3966.
6. Kessl JJ, Lange BB, Merbitz-Zahradnik T, Zwicker K, Hill P, Meunier B, Palsdottir H, Hunte C, Meshnick S, Trumpower BL: Molecular basis for atovaquone binding to the cytochrome bc1 complex. J Biol Chem 2003, 278:31312-31318.
7. Kessl JJ, Ha KH, Merritt AK, Lange BB, Hill P, Meunier B, Meshnick SR, Trumpower BL: Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J Biol Chem 2005, 280:17142-17148.
8. Chiodini PL, Conlon CP, Hutchinson DB, Farquhar JA, Hall AP, Peto TE, Birley H, Warrell DA: Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 1995, 36:1073-1078.
9. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ: Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996, 54:62-66.
10. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB: Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999, 60:533-541.
11. Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J: Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother 2006, 57:110-115.
12. Musset L, Bouchaud O, Matheron S, Massias L, Le Bras J: Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes and Infect 2006. doi:10.1016/j. micinf.2006.07.011
13. Srivastava I, Vadiya A: A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999, 43:1334-1339.
14. Anabwani G, Canfield CJ, Hutchinson DB: Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. Pediatr Infect Dis J 1999, 18:456-461.
15. Mulenga M, Sukwa TY, Canfield CJ, Hutchinson DB: Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin Ther 1999, 21:841-852.
16. Llanos-Cuentas A, Campos P, Clendenes M, Canfield CJ, Hutchinson DB: Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru. Braz J Infect Dis 2001, 5:67-72.
17. Camus D, Djossou F, Schilthuis HJ, Hogh B, Dutoit E, Malvy D, Roskell NS, Hedgley C, De Boever EH, Miller GB: Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis 2004, 38:1716-1723.
18. Petersen E: The safety of atovaquone/proguanil in long-term malaria prophylaxis of non-immune adults. J Travel Med 2003, 10(Suppl 1):S13-15. discussion S21
19. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB: Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 1999, 33:704-711.
20. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q: Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 2000, 44:2100-2108.
21. Suswam E, Kyle D, Lang-Unnasch N: Plasmodium falciparum: the effects of atovaquone resistance on respiration. Exp Parasitol 2001, 98:180-187.
22. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G: Malarone treatment failure and in vitro confirmationof resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J 2002, 1:1.
23. Fivelman QL, Adagu IS, Warhurst DC: Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother 2004, 48:4097-4102.
24. Farnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, Lindegardh N, Berezcky S, Bjorkman A: Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. Bmj 2003, 326:628-629.
25. Schwobel B, Alifrangis M, Salanti A, Jelinek T: Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J 2003, 2:5.
26. David KP, Alifrangis M, Salanti A, Vestergaard LS, Ronn A, Bygbjerg IB: Atovaquone/proguanil resistance in Africa: a case report. Scand J Infect Dis 2003, 35:897-898.
27. Kuhn S, Gill MJ, Kain KC: Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg 2005, 72:407-409.
28. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, Grobusch MP, Gascon J, Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C, Gjorup I, McWhinney P, Beran J, da Cunha S, Schulze M, Kollaritsch H, Kern P, Fry G, Richter J, European Network on Surveillance of Imported Infectious Diseases: Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis 2004, 190:1541-1546.
29. Gil JP, Nogueira F, Stromberg-Norklit J, Lindberg J, Carrolo M, Casimiro C, Lopes D, Arez AP, Cravo PV, Rosario VE: Detection of atovaquone and Malarone® resistance conferring mutations in Plasmodium falciparum cytochrome b gene (cytb). Mol Cell Probes 2003, 17:85-89.
30. Pimentel S, Nogueira F, Benchimol C, Quinhentos V, Bom J, Varandas L, do Rosario V, Bernardino L: Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola. Malar J 2006, 5:30.
31. Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AMJ: Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine- pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop 2005, 95:183-193.
32. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE: Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995, 52:565-568.
33. Edgar RC: MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004, 32:1792-1797.
34. Fisk DT, Meshnick S, Kazanjian PH: Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003, 36:70-78.
35. Basselin M, Hunt SM, Abdala-Valencia H, Kaneshiro ES: Ubiquinone synthesis in mitochondrial and microsomal subcellular fractions of Pneumocystis spp.: differential sensitivities to atovaquone. Eukaryot Cell 2005, 4:1483-1492.